CW June 2006
Volume 15Issue Number 6 June 2006 ISSN 10593802 Adding Docetaxel in Induction Chemotherapy for SCCHNBased on a 30% survival advantage among patients with squamous cell carcinoma of the head and neck (SCCHN), the lead investigator in a clinical trial of induction chemotherapy with three drugs (docetaxel/cisplatin/5-fluorouracil) (TPF) versus two drugs (PF), declared the combination a new induction therapy standard of care.
Go to Previous Page Go to Next Page Source & Additional Reading Presented at the American Society of Oncology 2006 Annual Meeting. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW June 2006Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
